MetLife Investment Management LLC Increases Stake in Vanda Pharmaceuticals Inc. $VNDA

MetLife Investment Management LLC increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 18.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,816 shares of the biopharmaceutical company’s stock after buying an additional 5,210 shares during the period. MetLife Investment Management LLC owned about 0.06% of Vanda Pharmaceuticals worth $151,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in VNDA. Quantinno Capital Management LP purchased a new stake in Vanda Pharmaceuticals during the 4th quarter worth approximately $48,000. Linden Thomas Advisory Services LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at approximately $49,000. Nations Financial Group Inc. IA ADV purchased a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at approximately $67,000. Virtu Financial LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at approximately $72,000. Finally, ProShare Advisors LLC increased its position in shares of Vanda Pharmaceuticals by 32.4% in the 4th quarter. ProShare Advisors LLC now owns 18,815 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 4,599 shares during the last quarter. 88.14% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the sale, the director owned 97,082 shares in the company, valued at $445,606.38. This represents a 6.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.90% of the stock is currently owned by corporate insiders.

Vanda Pharmaceuticals Price Performance

NASDAQ VNDA opened at $4.51 on Wednesday. The company has a market capitalization of $266.50 million, a price-to-earnings ratio of -3.99 and a beta of 0.74. The firm’s fifty day moving average price is $4.63 and its 200 day moving average price is $4.54. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $5.55.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). The business had revenue of $52.59 million for the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VNDA has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, August 21st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to data from MarketBeat, Vanda Pharmaceuticals presently has a consensus rating of “Strong Buy” and an average target price of $16.50.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.